Phase 4 Heart Disease Trial, Recruiting (NCT07225842)

Phase 4 Heart Disease Trial, Recruiting NCT07225842 Sponsor: University of Florida Condition: Heart Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07225842 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Heart Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are already receiving a specific blood-thinning medication called cangrelor, given through a drip at a standard dose, for at least two hours as part of their usual medical care
People aged 18 years or older
People who are willing and able to sign a written consent form agreeing to take part

Who may not be able to join:

People who need urgent or emergency surgery
People who are pregnant, possibly pregnant, or breastfeeding
People who have taken certain blood-thinning medications by mouth (including P2Y12 inhibitors or anticoagulants) or received a related injected medication (glycoprotein IIb/IIIa inhibitors) within the past 48 hours
People with a known allergy, sensitivity, or medical reason to avoid cangrelor or any of its ingredients, including mannitol, sorbitol, or microcrystalline cellulose (confirm with trial site if unsure about specific ingredients)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Dominick J Angiolillo, MD, PhD, University of Florida College of Medicine - Jacksonville

Phone: 904-244 2060

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07225842

Sponsor: University of Florida

Phase: Phase 4

Status: Recruiting

Condition: Heart Disease

Trial contact: 904-244 2060

More information: https://clinicaltrials.gov/study/NCT07225842

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are already receiving a specific blood-thinning medication called cangrelor, given through a drip at a standard dose, for at least two hours as part of their usual medical care
People aged 18 years or older
People who are willing and able to sign a written consent form agreeing to take part

Who may not be able to join:

People who need urgent or emergency surgery
People who are pregnant, possibly pregnant, or breastfeeding
People who have taken certain blood-thinning medications by mouth (including P2Y12 inhibitors or anticoagulants) or received a related injected medication (glycoprotein IIb/IIIa inhibitors) within the past 48 hours
People with a known allergy, sensitivity, or medical reason to avoid cangrelor or any of its ingredients, including mannitol, sorbitol, or microcrystalline cellulose (confirm with trial site if unsure about specific ingredients)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

University of Florida

Registry

ClinicalTrials.gov

Start date

18 February 2026

Est. completion

1 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Optimal platelet reactivity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov